Zentalis Pharmaceuticals Current Assets

Zentalis Pharmaceuticals posts a current assets of $180M as of June 2026. That compares with $310M in the prior-year period — down 41.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Zentalis Pharmaceuticals's current assets was $310M. The latest reading is $180M — a 41.8% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Zentalis Pharmaceuticals's financial statement story. At $180M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ZNTL's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Zentalis Pharmaceuticals's other metric pages and overview cover the third.

Judging Zentalis Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $180M here, then scan peer and history charts to see if the gap is persistent.